The search for a T cell line for testing novel antiviral strategies against HIV-1 isolates of diverse receptor tropism and subtype origin

Journal of Virological Methods

Volumn 203, Issue , 2014, Pages 88-96

  Herrera Carrillo, Elena ^a   Paxton, William A ^a   Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cell tropism; HIV 1; PM1 cells; RNAi therapy; Subtypes

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CELL LINE; DRUG EFFECTS; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PHYSIOLOGY; PROCEDURES; T LYMPHOCYTE; VIRAL TROPISM; VIROLOGY; VIRUS CULTURE;

ANTI-HIV AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HIV-1; HUMANS; T-LYMPHOCYTES; VIRAL TROPISM; VIRUS CULTIVATION;

EID: 84899023564     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.03.021     Document Type: Article

References (64)

1. Amado R.G., Mitsuyasu R.T., Rosenblatt J.D., Ngok F.K., Bakker A., Cole S., Chorn N., Lin L.S., Bristol G., Boyd M.P., et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum. Gene Ther. 2004, 15:251-262.
2. Anzinger J.J., Olinger G.G., Spear G.T. Donor variability in HIV binding to peripheral blood mononuclear cells. Virol. J. 2008, 5:95.
3. Baba M., Miyake H., Okamoto M., Iizawa Y., Okonogi K. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res. Hum. Retroviruses 2000, 16:935-941.
4. Beilke M.A., Japa S., Vinson D.G. HTLV-I and HTLV-II virus expression increase with HIV-1 coinfection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 17:391-397.
5. Bleul C.C., Wu L., Hoxie J.A., Springer T.A., Mackay C.R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1925-1930.
6. Centlivre M., Legrand N., Klamer S., Liu Y.P., Eije K.J., Bohne M., Rijnstra E.S., Weijer K., Blom B., Voermans C., et al. Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1. Mol. Ther. Nucleic Acids 2013, 2:e120.
7. Cervantes-Acosta G., Cohen E.A., Lemay G. Human Jurkat lymphocytes clones differ in their capacity to support productive human immunodeficiency virus type 1 multiplication. J. Virol. Methods 2001, 92:207-213.
8. Chen Z., Gettie A., Ho D.D., Marx P.A. Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. Virology 1998, 246:113-124.
9. Ciuffi A., Bleiber G., Munoz M., Martinez R., Loeuillet C., Rehr M., Fischer M., Gunthard H.F., Oxenius A., Meylan P., et al. Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J. Virol. 2004, 78:10747-10754.
10. Cornelissen M., Heeregrave E.J., Zorgdrager F., Pollakis G., Paxton W.A., van der Kuyl A.C. Generation of representative primary virus isolates from blood plasma after isolation of HIV-1 with CD44 MicroBeads. Arch. Virol 2010, 155:2017-2022.
11. Das A.T., Brummelkamp T.R., Westerhout E.M., Vink M., Madiredjo M., Bernards R., Berkhout B. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 2004, 78:2601-2605.
12. Dejucq N. HIV-1 replication in CD4+ T cell lines: the effects of adaptation on co-receptor use, tropism, and accessory gene function. J. Leukoc. Biol. 2000, 68:331-337.
13. Dejucq N., Simmons G., Clapham P.R. T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism. J. Gen. Virol. 2000, 81:2899-2904.
14. Deng H.K., Unutmaz D., Kewalramani V.N., Littman D.R. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997, 388:296-300.
15. Dianzani F., Antonelli G., Capobianchi M.R., De M.F. Replication of human immunodeficiency virus: yield of infectious virus under single growth cycle conditions. Arch. Virol 1988, 103:127-131.
16. Digiusto D.L., Krishnan A., Li L., Li H., Li S., Rao A., Mi S., Yam P., Stinson S., Kalos M., et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2010, 2:36-43.
17. Eekels J.J., Pasternak A.O., Schut A.M., Geerts D., Jeeninga R.E., Berkhout B. A competitive cell growth assay for the detection of subtle effects of gene transduction on cell proliferation. Gene Ther. 2011, 19:1058-1064.
18. Fauci A.S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988, 239:617-622.
19. Gao F., Robertson D.L., Carruthers C.D., Morrison S.G., Jian B., Chen Y., Barre-Sinoussi F., Girard M., Srinivasan A., Abimiku A.G., et al. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:5680-5698.
20. Geretti A.M. HIV-1 subtypes: epidemiology and significance for HIV management. Curr. Opin. Infect. Dis. 2006, 19:1-7.
21. Haasnoot J., Westerhout E.M., Berkhout B. RNA interference against viruses: strike and counterstrike. Nat. Biotechnol. 2007, 25:1435-1443.
22. Hahn B., Manzari V., Colombini S., Franchini G., Gallo R.C., Wong-Staal F. Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma. Nature 1983, 303:253-256.
23. Hamilton M.A., Russo R.C., Thurston R.V. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ. Sci. Technol. 1977, 11:714-719.
24. Harada S., Koyanagi Y., Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985, 229:563-566.
25. Harrowe G., Cheng-Mayer C. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. Virology 1995, 210:490-494.
26. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol. Med. 2012, 18:182-192.
27. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
28. Herrera-Carrillo E., Liu Y.P., Berkhout B. The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS. Mol. Ther. 2014, 22:596-606.
29. Hu W.S., Temin H.M. Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1556-1560.
30. Kiernan R., Marshall J., Bowers R., Doherty R., Mcphee D. Kinetics of HIV-1 replication and intracellular accumulation of particles in HTLV-I-transformed cells. AIDS Res. Hum. Retroviruses 1990, 6:743-752.
31. Klasse P.J., Boyd M.T., Weiss R.A., Schulz T.F. Mutations in the vpu, env, and nef genes of a syncytium-inducing variant of HIV type 1 JR-CSF that infects a range of T cell lines. AIDS Res. Hum. Retroviruses 1996, 12:347-350.
32. Kusagawa S., Sato H., Tomita Y., Tatsumi M., Kato K., Motomura K., Yang R., Takebe Y. Isolation and characterization of replication-competent molecular DNA clones of HIV type 1 CRF01_AE with different coreceptor usages. AIDS Res. Hum. Retroviruses 2002, 18:115-122.
33. Li M., Rossi J.J. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol. Biol. 2005, 309:261-272.
34. Liao F., Alkhatib G., Peden K.W., Sharma G., Berger E.A., Farber J.M. STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J. Exp. Med. 1997, 185:2015-2023.
35. Lusso P., Cocchi F., Balotta C., Markham P.D., Louie A., Farci P., Pal R., Gallo R.C., Reitz M.S. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 1995, 69:3712-3720.
36. Michienzi A., Castanotto D., Lee N., Li S., Zaia J.A., Rossi J.J. RNA-mediated inhibition of HIV in a gene therapy setting. Ann. N. Y. Acad. Sci. 2003, 1002:63-71.
37. Miyake H., Iizawa Y., Baba M. Novel reporter T-cell line highly susceptible to both. J. Clin. Microbiol. 2003, 41:2515-2521.
38. Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Ohtsuki Y., Shiraishi Y., Nagata K., Hinuma Y. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981, 294:770-771.
39. Paxton W.A., Martin S.R., Tse D., O'brien T.R., Skurnick J., Vandevanter N.L., Padian N., Braun J.F., Kotler D.P., Wolinsky S.M., et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat. Med. 1996, 2:412-417.
40. Peden K., Emerman M., Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1 LAI, HIV-1 MAL, and HIV-1 ELI. Virology 1991, 185:661-672.
41. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
42. Pollakis G., Abebe A., Kliphuis A., Chalaby M.I., Bakker M., Mengistu Y., Brouwer M., Goudsmit J., Schuitemaker H., Paxton W.A. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J. Virol. 2004, 78:2841-2852.
43. Popovic M., Sarngadharan M.G., Read E., Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224:497-500.
44. Princen K., Hatse S., Vermeire K., De C.E., Schols D. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology 2004, 1:2.
45. Roberts J.D., Bebenek K., Kunkel T.A. The accuracy of reverse transcriptase from HIV-1. Science 1988, 242:1171-1173.
46. Robertson D.L., Anderson J.P., Bradac J.A., Carr J.K., Foley B., Funkhouser R.K., Gao F., Hahn B.H., Kalish M.L., Kuiken C., et al. HIV-1 nomenclature proposal. Science 2000, 288:55-56.
47. Rucker J., Edinger A.L., Sharron M., Samson M., Lee B., Berson J.F., Yi Y., Margulies B., Collman R.G., Doranz B.J., et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 1997, 71:8999-9007.
48. Salter R.D., Howell D.N., Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985, 21:235-246.
49. Schneider U., Schwenk H.U., Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 1977, 19:621-626.
50. Smith S.D., Shatsky M., Cohen P.S., Warnke R., Link M.P., Glader B.E. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res. 1984, 44:5657-5660.
51. Tang S.B., Levy J.A. Inactivation of HIV-1 by trypsin and its use in demonstrating specific virus infection of cells. J. Virol. Methods 1991, 33:39-46.
52. Ter Brake O., Konstantinova P., Ceylan M., Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol. Ther. 2006, 14:883-892.
53. Thomson M.M., Najera R. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev. 2005, 7:210-224.
54. Trkola A., Paxton W.A., Monard S.P., Hoxie J.A., Siani M.A., Thompson D.A., Wu L., Mackay C.R., Horuk R., Moore J.P. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J. Virol. 1998, 72:396-404.
55. UNAIDS Reports on the Global AIDS Epidemic. Global AIDS Response Progress Reporting 2012.
56. van der Hoek L., Pollakis G., Lukashov V.V., Jebbink M.F., Jeeninga R.E., Bakker M., Dukers N., Jurriaans S., Paxton W.A., Back N.K., et al. Characterization of an HIV-1 group M variant that is distinct from the known subtypes. AIDS Res. Hum. Retroviruses 2007, 23:466-470.
57. van 't Wout A.B., Blaak H., Ran L.J., Brouwer M., Kuiken C., Schuitemaker H. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J. Virol. 1998, 72:5099-5107.
58. von Eije K.J., Ter Brake O., Berkhout B. Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J. Virol. 2008, 82:2895-2903.
59. von Eije K.J., Ter Brake O., Berkhout B. Stringent testing identifies highly potent and escape-proof anti-HIV short hairpin RNAs. J. Gene Med. 2009, 11:459-467.
60. Wainberg M.A., Brenner B.G. Role of HIV subtype diversity in the development of resistance to antiviral drugs. Viruses 2010, 2:2493-2508.
61. Wainberg M.A., Brenner B.G. The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs. Mol. Biol. Int. 2012, 2012:256982.
62. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905.
63. Westerhout E.M., Ooms M., Vink M., Das A.T., Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 2005, 33:796-804.
64. Wu L., Paxton W.A., Kassam N., Ruffing N., Rottman J.B., Sullivan N., Choe H., Sodroski J., Newman W., Koup R.A., et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 1997, 185:1681-1691.